Fujifilm Diosynth Biotechnologies Plans $2 Billion North Carolina Plant, 725 New Jobs

The Fujifilm Diosynth Biotechnologies facility in Holly Springs will be “North America’s largest end-to-end biopharmaceutical manufacturing facility,” Gov. Roy Cooper’s office said. The company, a subsidiary of Japanese conglomerate Fujifilm Corp., provides services from cell line and process development to clinical and FDA-approved commercial manufacturing for viral vaccines, viral vectors, recombinant proteins, monoclonal antibodies, and other “large-molecules and medical countermeasures.” The project is expected to create 725 new jobs, including engineers, scientists, manufacturing personnel, and support positions. State officials believe it will generate nearly $85 million in payroll and provide an economic impact of $5.5 billion over 12 years. “We are delighted to expand our footprint here in North Carolina as we fulfill our mission to help our customers accelerate development and supply of high-quality medicines to patients,” Fujifilm Corp. President Kenji Sukeno said in the announcement.